Skip to main content

Advertisement

Table 2 Treatment outcome

From: Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

  FOLFOX-4 (n = 29) Topotecan (n = 26)
Median follow-up, months (range) 45 (1–45) 57 (1–57)
Median PFS, months (95% CI) 2.8 (1.7–4.9) 2.8 (1.8–4.9)
Median OS, months (95% CI) 6.2 (2.4–14.6) 10.4 (4.9–19.5)
Tumor response, n (%)
 CR 1 (3.5) 1 (3.8)
 PR 5 (17.2) 1 (3.8)
 SD 8 (27.6) 6 (23.1)
 PD 15 (51.7) 18 (69.3)
Ca125 response*, n (%) 11 (44.0) 5 (26.3)
Number of patients receiving new treatment after progression, n (%) 16 (57.1) 17 (65.4)
  1. *According to Rustin’s criteria
  2. Abbreviations. CR complete response, FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, n number, PFS progression-free survival, PD progressive disease, PR partial response, OS overall survival, SD stable disease